We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Seeking Clues to Baxter (BAX) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that Baxter International (BAX - Free Report) will report quarterly earnings of $0.53 per share in its upcoming release, pointing to a year-over-year decline of 8.6%. It is anticipated that revenues will amount to $2.79 billion, exhibiting an increase of 1.5% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Baxter metrics that are routinely monitored and predicted by Wall Street analysts.
The combined assessment of analysts suggests that 'Net Sales- Pharmaceuticals' will likely reach $636.32 million. The estimate indicates a year-over-year change of -1%.
Analysts forecast 'Net Sales- Advanced Surgery' to reach $306.55 million. The estimate indicates a year-over-year change of +5%.
According to the collective judgment of analysts, 'Net Sales- Other' should come in at $68.32 million. The estimate points to a change of +469.4% from the year-ago quarter.
Analysts expect 'Net Sales- Front Line Care' to come in at $285.26 million. The estimate indicates a change of +1.9% from the prior-year quarter.
Based on the collective assessment of analysts, 'Net Sales- Pharmaceuticals- U.S.' should arrive at $200.71 million. The estimate indicates a year-over-year change of -6.2%.
It is projected by analysts that the 'Geographic Net Sales- International' will reach $1.24 billion. The estimate indicates a change of +0.1% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Net Sales- Advanced Surgery- U.S.' of $166.34 million. The estimate suggests a change of +6% year over year.
The consensus estimate for 'Net Sales- Advanced Surgery- International' stands at $138.24 million. The estimate indicates a year-over-year change of +2.4%.
Analysts predict that the 'Net Sales- Other- U.S.' will reach $38.69 million. The estimate points to a change of +867.3% from the year-ago quarter.
The consensus among analysts is that 'Net Sales- Other- International' will reach $21.85 million. The estimate suggests a change of +173.1% year over year.
The average prediction of analysts places 'Net Sales- Front Line Care- U.S.' at $212.84 million. The estimate indicates a year-over-year change of +2.3%.
Analysts' assessment points toward 'Net Sales- Front Line Care- International' reaching $71.26 million. The estimate suggests a change of -1% year over year.
Over the past month, shares of Baxter have returned +7.8% versus the Zacks S&P 500 composite's no change. Currently, BAX carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Seeking Clues to Baxter (BAX) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Wall Street analysts forecast that Baxter International (BAX - Free Report) will report quarterly earnings of $0.53 per share in its upcoming release, pointing to a year-over-year decline of 8.6%. It is anticipated that revenues will amount to $2.79 billion, exhibiting an increase of 1.5% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Baxter metrics that are routinely monitored and predicted by Wall Street analysts.
The combined assessment of analysts suggests that 'Net Sales- Pharmaceuticals' will likely reach $636.32 million. The estimate indicates a year-over-year change of -1%.
Analysts forecast 'Net Sales- Advanced Surgery' to reach $306.55 million. The estimate indicates a year-over-year change of +5%.
According to the collective judgment of analysts, 'Net Sales- Other' should come in at $68.32 million. The estimate points to a change of +469.4% from the year-ago quarter.
Analysts expect 'Net Sales- Front Line Care' to come in at $285.26 million. The estimate indicates a change of +1.9% from the prior-year quarter.
Based on the collective assessment of analysts, 'Net Sales- Pharmaceuticals- U.S.' should arrive at $200.71 million. The estimate indicates a year-over-year change of -6.2%.
It is projected by analysts that the 'Geographic Net Sales- International' will reach $1.24 billion. The estimate indicates a change of +0.1% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Net Sales- Advanced Surgery- U.S.' of $166.34 million. The estimate suggests a change of +6% year over year.
The consensus estimate for 'Net Sales- Advanced Surgery- International' stands at $138.24 million. The estimate indicates a year-over-year change of +2.4%.
Analysts predict that the 'Net Sales- Other- U.S.' will reach $38.69 million. The estimate points to a change of +867.3% from the year-ago quarter.
The consensus among analysts is that 'Net Sales- Other- International' will reach $21.85 million. The estimate suggests a change of +173.1% year over year.
The average prediction of analysts places 'Net Sales- Front Line Care- U.S.' at $212.84 million. The estimate indicates a year-over-year change of +2.3%.
Analysts' assessment points toward 'Net Sales- Front Line Care- International' reaching $71.26 million. The estimate suggests a change of -1% year over year.
View all Key Company Metrics for Baxter here>>>Over the past month, shares of Baxter have returned +7.8% versus the Zacks S&P 500 composite's no change. Currently, BAX carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .